Lewczuk, Piotr

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 2,065

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Hansson, O., Lehmann, S., Otto, M., Zetterberg, H., & Lewczuk, P. (2019) · Alzheimer's Research & Therapy

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 585

A practical guide to immunoassay method validation

Andreasson, U., Perret-Liaudet, A., van Waalwijk van Doorn, L. J. C., Blennow, K., Chiasserini, D., Engelborghs, S., Fladby, T., Genc, S., Kruse, N., Kuiperij, H. B., et al. (2015) · Frontiers in Neurology

Clinical Laboratory Practices and Quality ControlAdvanced Biosensing Techniques and Applications

Cited by 546

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Vanderstichele, H., Bibl, M., Engelborghs, S., Le Bastard, N., Lewczuk, P., Molinuevo, J. L., Parnetti, L., Perret‐Liaudet, A., Shaw, L. M., Teunissen, C., et al. (2012) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 358

Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment

Oeckl, P., Halbgebauer, S., Anderl-Straub, S., Steinacker, P., Huss, A. M., Neugebauer, H., von Arnim, C. A. F., Diehl-Schmid, J., Grimmer, T., Kornhuber, J., et al. (2019) · Journal of Alzheimer’s Disease

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 345

Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease

Welge, V., Fiege, O., Lewczuk, P., Mollenhauer, B., Esselmann, H., Klafki, H.-W., Wolf, S., Trenkwalder, C., Otto, M., Kornhuber, J., et al. (2009) · Journal of Neural Transmission

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 152

Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

Jansen, I. E., van der Lee, S. J., Gomez-Fonseca, D., de Rojas, I., Dalmasso, M. C., Grenier-Boley, B., Zettergren, A., Mishra, A., Ali, M., Andrade, V., et al. (2022) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 132

Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment

Wolfsgruber, S., Polcher, A., Koppara, A., Kleineidam, L., Frölich, L., Peters, O., Hüll, M., Rüther, E., Wiltfang, J., Maier, W., et al. (2017) · Journal of Alzheimer's Disease

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 114

Neurofilament ELISA validation

Petzold, A., Altintas, A., Andreoni, L., Bartos, A., Berthele, A., Blankenstein, M. A., Buee, L., Castellazzi, M., Cepok, S., Comabella, M., et al. (2010) · Journal of Immunological Methods

Clinical Laboratory Practices and Quality ControlReliability and Agreement in Measurement

Cited by 105

Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease

Mroczko, B., Groblewska, M., Litman-Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2018) · International Journal of Molecular Sciences

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 97

Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression

Clark, C., Lewczuk, P., Kornhuber, J., Richiardi, J., Maréchal, B., Karikari, T. K., Blennow, K., Zetterberg, H., & Popp, J. (2021) · Alzheimer's Research & Therapy

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 88

PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment

(ADNI), A. D. N. I., Kleineidam, L., Chouraki, V., Próchnicki, T., van der Lee, S. J., Madrid-Márquez, L., Wagner-Thelen, H., Karaca, I., Weinhold, L., Wolfsgruber, S., et al. (2020) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 62

SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease

Ramirez, A., van der Flier, W. M., Herold, C., Ramonet, D., Heilmann, S., Lewczuk, P., Popp, J., Lacour, A., Drichel, D., Louwersheimer, E., et al. (2014) · Human Molecular Genetics

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 49

Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer’s type

Martino Adami, P. V., Orellana, A., García, P., Kleineidam, L., Alarcón-Martín, E., Montrreal, L., Aguilera, N., Espinosa, A., Abdelnour, C., Rosende-Roca, M., et al. (2022) · Brain

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 46

Cerebrospinal Fluid Markers for Alzheimer's Disease over the Lifespan: Effects of Age and the APOEε4 Genotype

Popp, J., Lewczuk, P., Frommann, I., Kölsch, H., Kornhuber, J., Maier, W., & Jessen, F. (2010) · Journal of Alzheimer's Disease

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 36

Oligoclonal bands and kappa free light chains: Competing parameters or complementary biomarkers?

Konen, F. F., Wurster, U., Schwenkenbecher, P., Gerritzen, A., Groß, C. C., Eichhorn, P., Harrer, A., Isenmann, S., Lewczuk, P., Lewerenz, J., et al. (2025) · Autoimmunity Reviews

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 31